Hu Jiyi, Yang Zhongyi, Gao Jing, Hu Weixu, Yang Jing, Qiu Xianxin, Zhang Yingjian, Ma Guang, Kong Lin, Lu Jiade J
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.
Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy.
J Cancer. 2020 Oct 17;11(23):7073-7080. doi: 10.7150/jca.46490. eCollection 2020.
The purpose of this study was to investigate the role of 3'-deoxy-3'-[F]fluorothymidine (FLT)-PET for predicting the outcome of patients with locally recurrent nasopharyngeal carcinoma (LR-NPC) treated by carbon-ion radiotherapy (CIRT). Patients received FLT-PET/CT scan one-week prior to or after completion of CIRT were enrolled in the study. All patients were from prospective trials or treated using a standardized protocol. Time-dependent receiver operator characteristics (ROC) were used to determine the optimal cutoff values for FLT-PET parameters. Univariable and multivariable analyses of local progression-free survival (LPFS) were performed using Cox regression, to examine the prognostic value of FLT-PET parameters, including SUV, metabolic tumor volume (MTV) and total lesion thymidine (TLT). A total of 41 patients were enrolled. Elevated MTV and TLT were significantly associated with worse LPFS, in both univariable and multivariable analyses. ROC analysis revealed that both an MTV value higher than 8.6 and a TLT value higher than 14.9 were predictive of increased risk of developing local recurrence, the adjusted HRs were 5.59 (=0.009) and 7.76 (=0.002), respectively. In conclusion, FLT-PET was found to be a promising prognostic tool for LR-NPC patients and might play a role in the treatment guidance.
本研究旨在探讨3'-脱氧-3'-[F]氟胸腺嘧啶核苷(FLT)-PET在预测接受碳离子放疗(CIRT)的局部复发性鼻咽癌(LR-NPC)患者预后中的作用。在CIRT完成前或完成后一周接受FLT-PET/CT扫描的患者纳入本研究。所有患者均来自前瞻性试验或采用标准化方案治疗。使用时间依赖性受试者工作特征(ROC)曲线来确定FLT-PET参数的最佳临界值。采用Cox回归对局部无进展生存期(LPFS)进行单因素和多因素分析,以检验FLT-PET参数(包括SUV、代谢肿瘤体积(MTV)和总病变胸腺嘧啶(TLT))的预后价值。共纳入41例患者。单因素和多因素分析均显示,MTV和TLT升高与较差的LPFS显著相关。ROC分析显示,MTV值高于8.6和TLT值高于14.9均提示局部复发风险增加,校正后的HR分别为5.59(=0.009)和7.76(=0.002)。总之,FLT-PET被发现是LR-NPC患者一种有前景的预后评估工具,可能在治疗指导中发挥作用。